MX2021014193A - Moleculas de enlace biespecificas anti-ror1/anti-cd3. - Google Patents

Moleculas de enlace biespecificas anti-ror1/anti-cd3.

Info

Publication number
MX2021014193A
MX2021014193A MX2021014193A MX2021014193A MX2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A
Authority
MX
Mexico
Prior art keywords
ror1
binding molecules
bispecific binding
bispecific
bind
Prior art date
Application number
MX2021014193A
Other languages
English (en)
Spanish (es)
Inventor
Brian Lannutti
Katti Jessen
Jeffry D Watkins
Mira Ko
Thanh - Trang Vo
J Monty Watkins
Original Assignee
Velosbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velosbio Inc filed Critical Velosbio Inc
Publication of MX2021014193A publication Critical patent/MX2021014193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021014193A 2019-05-23 2020-05-22 Moleculas de enlace biespecificas anti-ror1/anti-cd3. MX2021014193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852039P 2019-05-23 2019-05-23
PCT/US2020/034281 WO2020237173A1 (en) 2019-05-23 2020-05-22 Anti-ror1/anti-cd3 bispecific binding molecules

Publications (1)

Publication Number Publication Date
MX2021014193A true MX2021014193A (es) 2022-01-06

Family

ID=71078637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014193A MX2021014193A (es) 2019-05-23 2020-05-22 Moleculas de enlace biespecificas anti-ror1/anti-cd3.

Country Status (11)

Country Link
US (1) US20220227866A1 (enExample)
EP (1) EP3972999A1 (enExample)
JP (1) JP7611171B2 (enExample)
KR (1) KR20220012313A (enExample)
CN (1) CN113874399B (enExample)
AU (1) AU2020277489A1 (enExample)
BR (1) BR112021023026A2 (enExample)
CA (1) CA3139111A1 (enExample)
MX (1) MX2021014193A (enExample)
TW (1) TWI899079B (enExample)
WO (1) WO2020237173A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
KR20220139916A (ko) * 2020-02-07 2022-10-17 벨로스바이오 인코포레이티드 항-ror1 항체 및 조성물
US20240392003A1 (en) * 2021-02-02 2024-11-28 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
US12545716B2 (en) 2021-07-19 2026-02-10 Immunome, Inc. Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023000791A1 (en) * 2021-07-23 2023-01-26 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
KR20240082402A (ko) * 2021-10-07 2024-06-10 내셔날 리서치 카운실 오브 캐나다 항-cd3 단일클론 항체 및 치료용 작제물
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
CA2881966C (en) * 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CA2899577C (en) 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR102638104B1 (ko) * 2014-07-25 2024-02-20 메모리얼 슬로안 케터링 캔서 센터 이특이적 her2 및 cd3 결합 분자
CA2963692A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3091032A1 (en) * 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
EP3405492B1 (en) * 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
JP2019506158A (ja) * 2016-01-22 2019-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
EP3574018A4 (en) * 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
CA3067829A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
KR20220139916A (ko) * 2020-02-07 2022-10-17 벨로스바이오 인코포레이티드 항-ror1 항체 및 조성물

Also Published As

Publication number Publication date
JP7611171B2 (ja) 2025-01-09
CN113874399A (zh) 2021-12-31
TWI899079B (zh) 2025-10-01
EP3972999A1 (en) 2022-03-30
WO2020237173A1 (en) 2020-11-26
US20220227866A1 (en) 2022-07-21
TW202110887A (zh) 2021-03-16
KR20220012313A (ko) 2022-02-03
AU2020277489A1 (en) 2021-11-25
BR112021023026A2 (pt) 2022-01-04
JP2022533418A (ja) 2022-07-22
CN113874399B (zh) 2025-07-11
CA3139111A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12021551487A1 (en) Tumor-targeted agonistic cd28 antigen binding molecules
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
JOP20200309A1 (ar) أجسام مضادة لـ il-11
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
ZA202100723B (en) Fc binding fragments comprising a cd137 antigen-binding site
NZ752044A (en) Anti-lag-3 antibodies and compositions
PH12022550509A1 (en) Anti-cd73 antibodies
PH12020552229A1 (en) Il-11ra antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12021552538A1 (en) Heavy chain antibodies binding to psma
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MY176475A (en) Human antibodies to pd-1
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.